CN106139019B - 一种改善痴呆症的中药组合物及其制备方法和应用 - Google Patents
一种改善痴呆症的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN106139019B CN106139019B CN201610649985.XA CN201610649985A CN106139019B CN 106139019 B CN106139019 B CN 106139019B CN 201610649985 A CN201610649985 A CN 201610649985A CN 106139019 B CN106139019 B CN 106139019B
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- chinese medicine
- dementia
- turmeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 206010012289 Dementia Diseases 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 141
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000000843 powder Substances 0.000 claims abstract description 40
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 31
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 30
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 30
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 30
- 235000013976 turmeric Nutrition 0.000 claims abstract description 30
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 28
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 28
- 244000294611 Punica granatum Species 0.000 claims abstract description 28
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 28
- 229940106134 krill oil Drugs 0.000 claims abstract description 28
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 28
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 28
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 28
- 241000572565 Alpinia oxyphylla Species 0.000 claims abstract description 27
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 27
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 27
- 229940094952 green tea extract Drugs 0.000 claims abstract description 27
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 27
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 27
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 26
- 241000605447 Anemarrhena Species 0.000 claims abstract description 26
- 229930191283 anemarrhena Natural products 0.000 claims abstract description 26
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 26
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 25
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 25
- 241000146384 Glaux Species 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 29
- 235000019441 ethanol Nutrition 0.000 claims description 27
- 238000010992 reflux Methods 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 230000003292 diminished effect Effects 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229920003081 Povidone K 30 Polymers 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 229940024898 povidone k30 Drugs 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 241001165494 Rhodiola Species 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 241000219095 Vitis Species 0.000 claims description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 4
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 241000239366 Euphausiacea Species 0.000 claims description 3
- 235000011201 Ginkgo Nutrition 0.000 claims description 3
- 241000218628 Ginkgo Species 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 230000004520 agglutination Effects 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 239000010779 crude oil Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 238000005461 lubrication Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000002893 slag Substances 0.000 claims 1
- 235000013616 tea Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 210000002569 neuron Anatomy 0.000 abstract description 8
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 4
- 230000001976 improved effect Effects 0.000 abstract description 4
- 238000012827 research and development Methods 0.000 abstract description 3
- 206010029350 Neurotoxicity Diseases 0.000 abstract description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000010534 mechanism of action Effects 0.000 abstract description 2
- 230000007135 neurotoxicity Effects 0.000 abstract description 2
- 231100000228 neurotoxicity Toxicity 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 12
- 230000008021 deposition Effects 0.000 description 9
- 238000000151 deposition Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种改善痴呆症的中药组合物及其制备方法和应用。本发明的一种改善痴呆症的中药组合物,包括以下组分:知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ‑氨基丁酸、南极磷虾油粉及石榴多酚。本发明的中药组合物可明显降低脑内β‑AP斑块面积,并且能够明显改善注射区周围及较远区域神经细胞的形态和数量,对β‑AP引起的神经元毒性具有保护作用。同时,本实验通过研究该中药组合物痴呆症动物模型的作用及作用机制,为进一步研发治疗痴呆症的中药提供了客观依据。
Description
技术领域
本发明涉及一种中药组合物,特别涉及一种改善痴呆症的中药组合物及其制备方法和应用,本发明属于中药技术领域。
背景技术
随着社会的发展和人口的老龄化,人们的精神卫生方面的疾病日益突出,尤其危害最严重的痴呆症,痴呆症的发病随年龄的增长而增加,是发生在老年期及老年前期的一种原发性脑萎缩,即在没有意识障碍的状态下,记忆、思维、分析判断、视空间辨认、情绪等方面的障碍。病人过着依赖性的生活。该病严重地影响病人的生活质量,给国家、社会和家庭带来沉重的负担。今后随着老年人口的增加,患病人数还会继续增加。因此,对痴呆症的防治是一个不容忽视的问题。世界各方面研究颇多,但至今仍无有效的治疗措施。
中药由于其含有多种化学成分,能够针对疾病的多个靶点,在治疗痴呆症这种多因素、多病理靶点的复杂性疾病方面具有独特的优势。大量的临床和实验资料显示,中药在延缓痴呆症进程、保护神经细胞、抑制氧化应激反应和抗兴奋性毒性等方面研究取得了一定进展。诸多研究显示了中医药治疗痴呆症的潜力和优越性。如果单纯用中医药能有效控制早期痴呆症症状,将可避免西药的毒副作用,从而为长期治疗痴呆症,有效控制痴呆症进程奠定基础,这或许是中医治疗痴呆症的发展方向。
发明内容
针对现有问题,本发明所要解决的技术问题是提供一种改善痴呆症的中药组合物及其制备方法和应用。
为了达到上述目的,本发明所采用的技术手段为:
一种改善痴呆症的中药组合物,包括以下组分:知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚。
所述的改善痴呆症的中药组合物,其特征在于,各组分的重量份为:知母提取物240~360份,银杏叶提取物240~360份,姜黄提取物160~240份,大豆卵磷脂240~360份、红景天提取物80~120份、远志提取物240~360份、益智仁提取物240~360份、绿茶提取物240~360份、葡萄籽提取物160~240份、磷酯酰丝氨酸160~240份、γ-氨基丁酸160~240份、南极磷虾油粉160~240份及石榴多酚80~120份。
优选的,所述的改善痴呆症的中药组合物,各组分的重量份为:知母提取物270~330份,银杏叶提取物270~330份,姜黄提取物180~220份,大豆卵磷脂270~330份、红景天提取物90~110份、远志提取物270~330份、益智仁提取物270~330份、绿茶提取物270~330份、葡萄籽提取物180~220份、磷酯酰丝氨酸180~220份、γ-氨基丁酸180~220份、南极磷虾油粉180~220份及石榴多酚90~110份。
更优选的,所述的改善痴呆症的中药组合物,各组分的重量份为:知母提取物300份,银杏叶提取物300份,姜黄提取物200份,大豆卵磷脂300份、红景天提取物100份、远志提取物300份、益智仁提取物300份、绿茶提取物300份、葡萄籽提取物200份、磷酯酰丝氨酸200份、γ-氨基丁酸200份、南极磷虾油粉200份及石榴多酚100份。
所述的改善痴呆症的中药组合物,其特征在于,各组分的制备方法如下:
知母提取物:将知母干燥、粉碎,用质量百分数为70-80%的乙醇回流提取2-3次,每次1.5-2h,每次料液比1-2:6-10,合并提取液,过滤,将滤液喷雾干燥成粉;
银杏叶提取物:将银杏叶干燥、粉碎,用质量百分数为60-70%乙醇回流提取2-3次,每次1-2h,每次料液比1-2:4-8,合并提取液,减压过滤,合并滤液,将滤液喷雾干燥成粉;
姜黄提取物:将姜黄根茎干燥后制成粉,用质量百分数为90-98%乙醇抽提1-2h,将提取液浓缩、结晶,干燥即得;
大豆卵磷脂:向大豆的毛油中加入质量百分数为2-3%的水,搅拌下加热至60-80℃,使磷脂水合成胶状的磷脂浆沉淀,离心分离,真空干燥脱水即得;
红景天提取物:将红景天干燥、粉碎,用质量百分数为65-75%乙醇回流提取2-3次,每次0.3-0.8h,每次料液比1-2:5-9,合并提取液,过滤,合并滤液,将滤液喷雾干燥成粉;
远志提取物:将远志干燥、粉碎,用质量百分数为90-98%乙醇回流提取2-3次,每次1-2h,每次料液比1-2:5-9,合并提取液,浓缩,0-10℃条件下放置,沉淀,过滤,弃去滤液,将滤渣干燥即得;
益智仁提取物:将益智仁干燥、粉碎,用质量百分数为65-75%乙醇回流提取2-3次,每次0.8-1.5h,每次料液比1-2:4-8,合并提取液,60℃以下减压过滤,浓缩,将浓缩液冷冻干燥成粉即得;
绿茶提取物:将绿茶干燥、粉碎,用质量百分数为75-85%乙醇回流提取2-3次,每次1-2h,每次料液比1-2:8-10,合并提取液,过滤、浓缩,将浓缩液干燥即得;
葡萄籽提取物:将葡萄籽干燥、粉碎,用质量百分数为75-85%乙醇回流提取2次,第一次料液比为1-2:9-10,提取1.25-1.75h,第二次料液比为1-2:7-8,提取0.75-1.25h,合并两次提取液,过滤,将滤液喷雾干燥成粉;
南极磷虾油粉:将磷虾洗净、破碎,用质量百分数为80-85%的乙醇回流提取,将提取液浓缩、将浓缩液干燥即得;
石榴多酚:将干燥石榴皮粉碎后,用质量百分数为65-75%乙醇加热回流提取2.5-3.5h,提取2-3次,合并提取液,40℃减压过滤,合并滤液,浓缩,将浓缩液冷冻干燥成粉。
本发明所述的改善痴呆症的中药组合物,按照中药常规制药方法制备成临床所用的任何一种药物制剂。
本发明所述的改善痴呆症的中药组合物制成胶囊剂的方法,包括以下步骤:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入或者不加入二氧化硅或硬脂酸镁,灌装胶囊,即得。
本发明所述的改善痴呆症的中药组合物制成粉剂的方法,包括以下步骤:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入或者不加入二氧化硅或硬脂酸镁,以粉剂装袋,即得。
本发明所述的改善痴呆症的中药组合物制成片剂的方法,包括以下步骤:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入微晶纤维素、羧甲基淀粉钠,并用聚维酮k30造粒,然后加入润滑剂,压片,即得。
本发明所述的改善痴呆症的中药组合物制成颗粒剂的方法,包括以下步骤:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入微晶纤维素、羧甲基淀粉钠,并用聚维酮k30造粒,装袋,即得。
本发明所述的改善痴呆症的中药组合物在制备改善痴呆症的药物及保健品中的应用。
本发明的中药组合物可明显降低脑内β-AP斑块面积,并且能够明显改善注射区周围及较远区域神经细胞的形态和数量,对β-AP引起的神经元毒性具有保护作用。同时,本实验通过研究该中药组合物痴呆症动物模型的作用及作用机制,为进一步研发治疗痴呆症的中药提供了客观依据。
具体实施方式
下面结合具体实施例来进一步描述本发明,本发明的优点和特点将会随着描述而更为清楚。但实施例仅是范例性的,并不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换,但这些修改和替换均落入本发明的保护范围内。
实施例1中药组合物中各组分的制备
知母提取物:将知母干燥、粉碎,用质量百分数为75%的乙醇回流提取3次,每次2h,每次料液比1:8,合并提取液,过滤,将滤液喷雾干燥成粉;
银杏叶提取物:将银杏叶干燥、粉碎,用质量百分数为65%乙醇回流提取3次,每次1.5h,每次料液比1:6,合并提取液,减压过滤,合并滤液,将滤液喷雾干燥成粉;
姜黄提取物:将姜黄根茎干燥后制成粉,用质量百分数为95%乙醇抽提1h,将提取液浓缩、结晶,干燥即得;
大豆卵磷脂:向大豆的毛油中加入质量百分数为2-3%的水,搅拌下加热至75℃,使磷脂水合成胶状的磷脂浆沉淀,离心分离,真空干燥脱水即得;
红景天提取物:将红景天干燥、粉碎,用质量百分数为70%乙醇回流提取3次,每次0.5h,每次料液比1:7,合并提取液,过滤,合并滤液,将滤液喷雾干燥成粉;
远志提取物:将远志干燥、粉碎,用质量百分数为95%乙醇回流提取3次,每次1.5h,每次料液比1:7,合并提取液,浓缩,0-5℃条件下放置,沉淀,过滤,弃去滤液,将滤渣干燥即得;
益智仁提取物:将益智仁干燥、粉碎,用质量百分数为70%乙醇回流提取3次,每次1h,每次料液比1:6,合并提取液,60℃以下减压过滤,浓缩,将浓缩液冷冻干燥成粉即得;
绿茶提取物:将绿茶干燥、粉碎,用质量百分数为80%乙醇回流提取3次,每次1.5h,每次料液比1:9,合并提取液,过滤、浓缩,将浓缩液干燥即得;
葡萄籽提取物:将葡萄籽干燥、粉碎,用质量百分数为80%乙醇回流提取2次,第一次料液比为1:10,提取1.5h,第二次料液比为1:8,提取1h,合并两次提取液,过滤,将滤液喷雾干燥成粉;
南极磷虾油粉:将磷虾洗净、破碎,用质量百分数为85%的乙醇回流提取,将提取液浓缩、将浓缩液干燥即得;
石榴多酚:将干燥石榴皮粉碎后,用质量百分数为70%乙醇加热回流提取3h,提取2-3次,合并提取液,40℃减压过滤,合并滤液,浓缩,将浓缩液冷冻干燥成粉。
γ-氨基丁酸及磷酯酰丝氨酸均为购买得到。
实施例2中药组合物的胶囊剂制备
称取按照实施例1制备的:知母提取物300g,银杏叶提取物300g,姜黄提取物200g,大豆卵磷脂300g、红景天提取物100g、远志提取物300g、益智仁提取物300g、绿茶提取物300g、葡萄籽提取物200g、磷酯酰丝氨酸200g、γ-氨基丁酸200g、南极磷虾油粉200g及石榴多酚100g。
将上述中药组合物制备为胶囊剂的方法:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入二氧化硅4g,灌装胶囊,即得,其中,每粒胶囊含上述中药组合物0.5g。
实施例3中药组合物的粉剂制备
称取按照实施例1制备的:知母提取物260g,银杏叶提取物300g,姜黄提取物180g,大豆卵磷脂320g、红景天提取物90g、远志提取物340g、益智仁提取物280g、绿茶提取物320g、葡萄籽提取物240g、磷酯酰丝氨酸180g、γ-氨基丁酸200g、南极磷虾油粉210g及石榴多酚110g。
将上述中药组合物制备为粉剂的方法:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入硬脂酸镁10g,以粉剂装袋,即得,其中,每袋含上述中药组合物1.5g。
实施例4中药组合物的片剂制备
称取按照实施例1制备的:知母提取物320g,银杏叶提取物340g,姜黄提取物220g,大豆卵磷脂260g、红景天提取物120g、远志提取物250g、益智仁提取物320g、绿茶提取物270g、葡萄籽提取物180g、磷酯酰丝氨酸230g、γ-氨基丁酸220g、南极磷虾油粉180g及石榴多酚90g。
将上述中药组合物制备为片剂的方法:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入微晶纤维素220g及羧甲基淀粉钠50g,并用加入聚维酮k3030g,造粒,加入润滑剂10g,压片,即得,其中,每片含上述中药组合物0.5g。
实施例5中药组合物的颗粒剂制备
称取按照实施例1制备的:知母提取物300g,银杏叶提取物270g,姜黄提取物240g,大豆卵磷脂280g、红景天提取物80g、远志提取物280g、益智仁提取物345g、绿茶提取物350g、葡萄籽提取物230g、磷酯酰丝氨酸160g、γ-氨基丁酸170g、南极磷虾油粉230g及石榴多酚120g。
将上述中药组合物制备为颗粒剂的方法:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入微晶纤维素220g及羧甲基淀粉钠50g,并用加入聚维酮k3030g,造粒,装袋,即得。其中,每袋颗粒剂含有上述中药组合物1.5g。
实施例6在本发明的中药组合物在临床上的应用
1.实验材料
1.1实验药品
所用的受试物为实施例1制备得到的胶囊剂。
β-AP25-35;鹅膏蕈氨酸(IBO),以无菌生理盐水配制成2g/L;以上均为Sigma公司产品。
1.2实验动物
选用军事医学科学院实验动物中心繁殖的成年雄性SD大鼠(220~250g)60只,实验动物使用许可证号SYXK(京)2012-0020。
1.3试验设备
CM-1900冷冻切片机,德国LEICA公司产品;BH-2型OLYMPUS带摄影头显微镜,日本OLYMPUS公司产品;KS400型计算机图像分析仪,德国KAISER公司产品。
2.试验方法
2.1SD大鼠饲养
手术前饲养1周,自由饮食,室温20-22℃,每日光照12h。
2.2SD大鼠分组
将动物随机分成5组(每组12只):对照组、模型组、模型+受试物低剂量组、模型+受试物中剂量组、模型+受试物高剂量组,低、中、高三个剂量组的每天的剂量分别为人体每天推荐剂量的2.5倍,5倍,15倍,人体每天推荐剂量为50mg/日/kg体重,也即125mg/日/kg体重,250mg/日/kg体重,750mg/日/kg体重。
2.3SD大鼠痴呆模型
对SD大鼠行脑部定位,右侧单侧注射β-AP25-35。每只模型组和受试物组SD大鼠用注射器一次注射β-AP25-35和IBO的混合液1μL,对照组同侧注射1μL无菌生理盐水。
术后4天起,灌胃体积为0.5ml/100g大鼠,受试物组大鼠每日灌胃受试物质量浓度为5%的CMC-Na混悬液,对照组和模型组大鼠每日灌胃等体积质量浓度为5%的CMC-Na溶媒。连续灌胃30d。
末次给药后,断头处死动物,取大脑右半球,立即冷冻,用冷冻切片机作冠状切片,片厚为6μm。染色,用中性树胶封固。
2.4显微摄影与图像分析
在40倍镜下观察注射β-AP25-35形成的沉积斑块呈黄色斑点,边缘清晰。5组样本选择相同部位,每张切片选2个视野。摄影时,在显微镜下寻找到所需部位,调好焦距,用100倍镜拍摄。每组随机选取1个切片,每个切片随机选取1个斑块,用计算机图像分析仪进行灰度测定,以100-152为标准灰度值范围。每个斑块测定斑点面积和整个切片总面积的比值,比值(%)=斑点面积/总面积×100%。比值越大,则表明斑点数量或面积越大,最后用t检验进行统计处理。
2.5脑组织中胆碱乙酰转移酶(ChAT)活性的测定
ChAT的活性以形成的乙酰胆碱(Achnmol/h/mg prot)表示。
2.6脑内M受体密度测定
用3H-QNB单点法测定脑总M受体密度,Lowry法测定脑蛋白密度。受体密度以MR值(fmol/mg prot)表示。
3.实验结果
3.1斑块沉积和神经细胞形态学的变化
通过显微摄影与图像分析发现,SD大鼠脑内注射β-AP25-35+IBO 30d后,脑切片染色显示,模型组多数切片上都可见到黄色沉积物。从形态上看,大多集中呈一块斑块,有的切片中分散成几个小斑块或斑点。受试物组的切片中也可见到类似的黄色沉积斑,个别切片也可见到针头行进轨迹,但切片的沉积面积较模型组小。在β-AP斑块周围或附近,可见到基底核神经元发生变性和数量减少,如细胞出现溃破、空泡、固缩和胞核减少等死亡现象,以斑块周围神经元变性最明显。
3.2受试物对SD痴呆模型大鼠脑内β-AP沉积斑块灰度值和神经细胞的影响
用图像分析仪求出每一切片黄色沉积斑块的总面积,求出各组面积的均值及标准差,结果见表1。可以看出,脑内注射生理盐水的动物脑片无任何黄色物沉积。而模型组动物脑片沉积斑块面积则比较大,模型+受试物组动物脑片β-AP沉积斑块面积和数量均明显比模型组少,统计表明均值都是模型组大于模型+受试物组,P<0.05。此外还发现,模型+受试物组动物脑内β-AP沉积斑块周围及较远区域神经细胞数量明显比模型组多,细胞形态恢复较好,染色显示胞核显著增多。这表明,受试物对β-AP的沉积可能有清除效果并有助于保护神经细胞。
表1 受试物对痴呆模型大鼠脑内β-AP沉积斑块面积的影响(x±s)
*与模型组比较,P<0.05
3.3受试物对SD痴呆模型大鼠脑组织中胆碱乙酰转移酶ChAT活性的影响
由表2可看出,模型组大鼠脑中ChAT活性明显低于对照组,这表明,β-AP对ChAT活性有抑制作用。而当SD模型大鼠灌胃受试物30d后,ChAT活性明显升高,这表明,受试物对β-AP引起的ChAT活性降低有提高作用。
3.4受试物对SD痴呆模型大鼠脑内总M受体密度的影响
表2表明脑内一次注射β-AP,模型组大鼠脑内总M受体密度始终低于正常对照组,说明β-AP能减少脑M受体密度,而当SD模型大鼠灌胃受试物30d后,M受体密度又明显升高,这表明,受试物能明显改善β-AP引起的M受体密度降低。
表2 受试物对痴呆模型大鼠脑ChAT活性及脑总M受体密度的影响(x±s)
*与对照组比较,P<0.01;**与模型组比较,P<0.01
以上实验通过研究本发明的中药组合物对痴呆症动物模型的治疗作用及作用机制,为进一步研发治疗痴呆症的新药提供了客观依据。
Claims (10)
1.一种改善痴呆症的中药组合物,其特征在于,原料药由以下组分组成:知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚;
各组分的重量份为:知母提取物240~360份,银杏叶提取物240~360份,姜黄提取物160~240份,大豆卵磷脂240~360份、红景天提取物80~120份、远志提取物240~360份、益智仁提取物240~360份、绿茶提取物240~360份、葡萄籽提取物160~240份、磷酯酰丝氨酸160~240份、γ-氨基丁酸160~240份、南极磷虾油粉160~240份及石榴多酚80~120份。
2.如权利要求1所述的改善痴呆症的中药组合物,其特征在于,各组分的重量份为:知母提取物270~330份,银杏叶提取物270~330份,姜黄提取物180~220份,大豆卵磷脂270~330份、红景天提取物90~110份、远志提取物270~330份、益智仁提取物270~330份、绿茶提取物270~330份、葡萄籽提取物180~220份、磷酯酰丝氨酸180~220份、γ-氨基丁酸180~220份、南极磷虾油粉180~220份及石榴多酚90~110份。
3.如权利要求1所述的改善痴呆症的中药组合物,其特征在于,各组分的重量份为:知母提取物300份,银杏叶提取物300份,姜黄提取物200份,大豆卵磷脂300份、红景天提取物100份、远志提取物300份、益智仁提取物300份、绿茶提取物300份、葡萄籽提取物200份、磷酯酰丝氨酸200份、γ-氨基丁酸200份、南极磷虾油粉200份及石榴多酚100份。
4.如权利要求1所述的改善痴呆症的中药组合物,其特征在于,各组分的制备方法如下:
知母提取物:将知母干燥、粉碎,用质量百分数为70-80%的乙醇回流提取2-3次,每次1.5-2h,每次料液比1-2:6-10,合并提取液,过滤,将滤液喷雾干燥成粉;
银杏叶提取物:将银杏叶干燥、粉碎,用质量百分数为60-70%乙醇回流提取2-3次,每次1-2h,每次料液比1-2:4-8,合并提取液,减压过滤,合并滤液,将滤液喷雾干燥成粉;
姜黄提取物:将姜黄根茎干燥后制成粉,用质量百分数为90-98%乙醇抽提1-2h,将提取液浓缩、结晶,干燥即得;
大豆卵磷脂:向大豆的毛油中加入质量百分数为2-3%的水,搅拌下加热至60-80℃,使磷脂水合成胶状的磷脂浆沉淀,离心分离,真空干燥脱水即得;
红景天提取物:将红景天干燥、粉碎,用质量百分数为65-75%乙醇回流提取2-3次,每次0.3-0.8h,每次料液比1-2:5-9,合并提取液,过滤,合并滤液,将滤液喷雾干燥成粉;
远志提取物:将远志干燥、粉碎,用质量百分数为90-98%乙醇回流提取2-3次,每次1-2h,每次料液比1-2:5-9,合并提取液,浓缩,0-10℃条件下放置,沉淀,过滤,弃去滤液,将滤渣干燥即得;
益智仁提取物:将益智仁干燥、粉碎,用质量百分数为65-75%乙醇回流提取2-3次,每次0.8-1.5h,每次料液比1-2:4-8,合并提取液,60℃以下减压过滤,浓缩,将浓缩液冷冻干燥成粉即得;
绿茶提取物:将绿茶干燥、粉碎,用质量百分数为75-85%乙醇回流提取2-3次,每次1-2h,每次料液比1-2:8-10,合并提取液,过滤、浓缩,将浓缩液干燥即得;
葡萄籽提取物:将葡萄籽干燥、粉碎,用质量百分数为75-85%乙醇回流提取2次,第一次料液比为1-2:9-10,提取1.25-1.75h,第二次料液比为1-2:7-8,提取0.75-1.25h,合并两次提取液,过滤,将滤液喷雾干燥成粉;
南极磷虾油粉:将磷虾洗净、破碎,用质量百分数为80-85%的乙醇回流提取,将提取液浓缩、将浓缩液干燥即得;
石榴多酚:将干燥石榴皮粉碎后,用质量百分数为65-75%乙醇加热回流提取2.5-3.5h,提取2-3次,合并提取液,40℃减压过滤,合并滤液,浓缩,将浓缩液冷冻干燥成粉。
5.由权利要求1-4任一项所述的改善痴呆症的中药组合物按照中药常规制药方法制备成的临床所用的药物制剂。
6.将权利要求1-4任一项所述的改善痴呆症的中药组合物制成胶囊剂的方法,其特征在于,包括以下步骤:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入或者不加入二氧化硅或硬脂酸镁,灌装胶囊,即得。
7.将权利要求1-4任一项所述的改善痴呆症的中药组合物制成粉剂的方法,其特征在于,包括以下步骤:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入或者不加入二氧化硅或硬脂酸镁,以粉剂装袋,即得。
8.将权利要求1-4任一项所述的改善痴呆症的中药组合物制成片剂的方法,其特征在于,包括以下步骤:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入微晶纤维素、羧甲基淀粉钠,并用聚维酮k30造粒,然后加入润滑剂,压片,即得。
9.将权利要求1-4任一项所述的改善痴呆症的中药组合物制成颗粒剂的方法,其特征在于,包括以下步骤:
将知母提取物、银杏叶提取物、姜黄提取物、大豆卵磷脂、红景天提取物、远志提取物、益智仁提取物、绿茶提取物、葡萄籽提取物、磷酯酰丝氨酸、γ-氨基丁酸、南极磷虾油粉及石榴多酚混合均匀后,加入微晶纤维素、羧甲基淀粉钠,并用聚维酮k30造粒,装袋,即得。
10.如权利要求1-4任一项所述的改善痴呆症的中药组合物在制备改善痴呆症的药物或保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610649985.XA CN106139019B (zh) | 2016-08-10 | 2016-08-10 | 一种改善痴呆症的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610649985.XA CN106139019B (zh) | 2016-08-10 | 2016-08-10 | 一种改善痴呆症的中药组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106139019A CN106139019A (zh) | 2016-11-23 |
CN106139019B true CN106139019B (zh) | 2019-10-01 |
Family
ID=57328956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610649985.XA Active CN106139019B (zh) | 2016-08-10 | 2016-08-10 | 一种改善痴呆症的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106139019B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109331143B (zh) * | 2018-10-30 | 2022-07-08 | 河西学院 | 一种苁蓉复合物及其制法 |
EP3873434A1 (en) * | 2018-11-04 | 2021-09-08 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Nasal compositions and methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101168025A (zh) * | 2007-10-25 | 2008-04-30 | 张占军 | 一种防治老年性痴呆的药物组合物 |
CN102028220A (zh) * | 2011-01-07 | 2011-04-27 | 济南老来寿生物股份有限公司 | 一种改善老年痴呆的功能性食品 |
CN103041060A (zh) * | 2013-01-21 | 2013-04-17 | 李庆杰 | 一种有助于改善记忆力,辅助治疗老年痴呆的药物组合物 |
-
2016
- 2016-08-10 CN CN201610649985.XA patent/CN106139019B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101168025A (zh) * | 2007-10-25 | 2008-04-30 | 张占军 | 一种防治老年性痴呆的药物组合物 |
CN102028220A (zh) * | 2011-01-07 | 2011-04-27 | 济南老来寿生物股份有限公司 | 一种改善老年痴呆的功能性食品 |
CN103041060A (zh) * | 2013-01-21 | 2013-04-17 | 李庆杰 | 一种有助于改善记忆力,辅助治疗老年痴呆的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN106139019A (zh) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20120059207A (ko) | 동충하초 추출물 또는 이로부터 분리된 코디세핀을 유효성분으로 하는 불면증 개선 및 치료용 약학 조성물 | |
CN104225524B (zh) | 栝楼桂枝汤在制备治疗或/和预防认知功能障碍的药物中的用途 | |
TW201542219A (zh) | 養血清腦製劑在製備治療阿爾茨海默症的藥物中的應用 | |
CN106139019B (zh) | 一种改善痴呆症的中药组合物及其制备方法和应用 | |
JP2019535833A (ja) | 腫瘍治療用の漢方薬組成物及びその製造方法と用途 | |
CN104922216B (zh) | 一种通便的药物组合物及其制备方法 | |
CN109718273A (zh) | 紫苏叶提取物在预防或治疗骨性关节炎中的应用 | |
CN105726622A (zh) | 一种抗疲劳的中药组合提取物及其制备方法和应用 | |
CN101380359B (zh) | 健骨胶囊及其制备方法 | |
CN105055785B (zh) | 一种治疗糖尿病视网膜病变的中药组合物 | |
EP0652762B1 (de) | Neuartiges anxiolytikum | |
CN109260397A (zh) | 一种治疗眼底血管性疾病的中药组合物 | |
CN108434166A (zh) | 一种血塞通药物组合物及其制备方法、制剂与应用 | |
CN104147380A (zh) | 一种具有缓解视疲劳作用的药物组合物、制备方法及应用 | |
JP2016013991A (ja) | 抗子宮筋腫用の漢方薬草合成物およびその抽出物の用途 | |
CN102119960B (zh) | 一种用于活血化瘀、益气通脉的药物组合物 | |
CN100370973C (zh) | 一种治疗胸痹的中药制剂 | |
CN106727928A (zh) | 夏枯草提取物及制备方法及应用 | |
CN102188592A (zh) | 一种***化疗后血小板减少的药物及其制备方法 | |
CN102920845B (zh) | 一种治疗眼底黄斑变性的中药组合物及其制备方法 | |
CN105816549B (zh) | 一种防治动脉粥样硬化斑块的药物及其制备方法 | |
Tortoriello et al. | New anxiolytic phytopharmaceutical elaborated with the standardized extract of Galphimia glauca | |
CN108685961A (zh) | 一种改善学习记忆组合物及制剂,其制备方法及应用 | |
CN100500134C (zh) | 一种提高金鸡制剂生物利用度及药效的制剂和制备方法及用途 | |
CN107789568A (zh) | 一种新健脑补肾中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |